March 23 (Reuters) - Willow Biosciences Inc WLLW.TO :
* WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2020 YEAR END RESULTS AND OPERATIONAL UPDATE
* ON TRACK TO COMMERCIALIZE ITS FIRST CANNABINOID, CBG, IN Q1 2021
* FIRST SALES OF CBG EXPECTED TO OCCUR IN Q2 2021
* DURING REMAINDER OF 2021, WILLOW WILL CONTINUE TO OPTIMIZE ITS COMMERCIAL PROCESS FOR CBG
* EXPECTS 2022 TO BE CBG'S FIRST FULL YEAR OF COMMERCIAL PRODUCTION AND SALES
* WILLOW BIOSCIENCES - PLANS TO UPDATE MARKET ON WHICH CANNABINOID IT INTENDS TO COMMERCIALIZE NEXT LATER THIS YEAR AND INTO 2022